NxStage Medical (NXTM) Scheduled to Post Quarterly Earnings on Thursday
NxStage Medical (NASDAQ:NXTM) is scheduled to issue its Q114 quarterly earnings data on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.11) per share and revenue of $69.44 million for the quarter. NxStage Medical has set its Q1 guidance at (0.12)-(0.11) EPS and its FY14 guidance at (0.44)-(0.37) EPS.
NxStage Medical (NASDAQ:NXTM) last announced its earnings results on Thursday, February 27th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.01. The company had revenue of $69.40 million for the quarter, compared to the consensus estimate of $67.66 million. During the same quarter in the previous year, the company posted ($0.04) earnings per share. The company’s revenue for the quarter was up 6.9% on a year-over-year basis. On average, analysts expect NxStage Medical to post $-0.42 EPS for the current fiscal year and $-0.27 EPS for the next fiscal year.
NxStage Medical (NASDAQ:NXTM) traded down 0.18% on Wednesday, hitting $11.04. The stock had a trading volume of 250,562 shares. NxStage Medical has a 52-week low of $8.77 and a 52-week high of $15.00. The stock has a 50-day moving average of $12.4 and a 200-day moving average of $12.05. The company’s market cap is $675.9 million.
A number of research firms have recently commented on NXTM. Analysts at Wells Fargo & Co. downgraded shares of NxStage Medical from a “market perform” rating to an “underperform” rating in a research note on Tuesday, March 11th. On a related note, analysts at Jefferies Group raised their price target on shares of NxStage Medical from $13.00 to $17.00 in a research note on Friday, February 28th. Finally, analysts at Leerink Swann raised their price target on shares of NxStage Medical from $15.00 to $18.00 in a research note on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the stock. NxStage Medical currently has a consensus rating of “Hold” and a consensus price target of $17.17.
NxStage Medical, Inc (NASDAQ:NXTM) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.